Pegcetacoplan clinical trials
Also written APL-2, Empaveli and SYFOVRE.
How each study uses pegcetacoplan is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the pegcetacoplan studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 14 May 2021 · EMPAVELI · NDA 215014 (FDA, Drugs@FDA)
- European Union
- 13 Dec 2021 · Aspaveli · EMEA/H/C/005553 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
32 studies that test it; most in 2018 (8); 1 more planned to start later
| Year | Studies |
|---|---|
| 2015 | 4 |
| 2017 | 1 |
| 2018 | 8 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 4 |
| 2022 | 2 |
| 2023 | 2 |
| 2025 | 4 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 30 · Other 3
Apellis Pharmaceuticals, Inc. (24) · Swedish Orphan Biovitrum (4) · Roswell Park Cancer Institute (2) · Columbia University (1) · AbbVie (1) · Hoffmann-La Roche (1)
Often tested with
Tested in the same studies.
ABBV-6628 (1) · RO7669330 (1) · Avacincaptad pegol (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3, 1 in phase 3
Studies that test pegcetacoplan, phase 3 first.
- Jul 2027An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative GlomerulonephritisPhase 3 · Apellis Pharmaceuticals, Inc.
- Apr 2027Safely Quenching Complement in Stroke SurvivorsPhase 1 · Columbia University
- Jun 2027A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular DegeneratioPhase 2 · Apellis Pharmaceuticals, Inc.
Studies
Open first, then newest update. How each study uses pegcetacoplan is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 33
- A Study to Assess the Efficacy and Safety of Pegcetacoplan for the Prevention of Recurrent C3G or Primary IC-MPGN in Kidney Transplant RecipientsRecruitingPhase 3Swedish Orphan BiovitrumNCT07898774Written as Pegcetacoplan
- Real-World Effectiveness and Safety of Pegcetacoplan in Patients With C3G or IC-MPG: A Multi-Country StudyRecruitingPhase 4Swedish Orphan BiovitrumNCT07746895Written as Pegcetacoplan
- A Sequential Phase 2/3 Study of APL2 in Patients With Focal Segmental GlomerulosclerosisRecruitingPhase 2/3Apellis Pharmaceuticals, Inc.NCT07213960Written as APL2
- Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal AdenocarcinomaRecruitingPhase 1/2Roswell Park Cancer InstituteNCT07214298Written as Pegcetacoplan
- Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular DegenerationRecruitingPhase 1/2AbbVieNCT07160179Written as SYFOVRE
- A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)RecruitingPhase 2Apellis Pharmaceuticals, Inc.NCT04901936Written as Pegcetacoplan
- A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular DegeneratioRecruitingPhase 2Apellis Pharmaceuticals, Inc.NCT07215390Written as APL-3007, pegcetacoplan (APL-2)
- Safely Quenching Complement in Stroke SurvivorsNot yet recruitingPhase 1Columbia UniversityNCT07495722Written as Pegcetacoplan Injection [Empaveli]
- APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant EffusionRecruitingPhase 2Roswell Park Cancer InstituteNCT04919629Written as Pegcetacoplan
- Pegcetacoplan Long Term Safety and Efficacy Extension StudyCompletedPhase 3Apellis Pharmaceuticals, Inc.NCT03531255Written as Pegcetacoplan
- A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)TerminatedPhase 1Hoffmann-La RocheNCT06961370Written as Syfovre™
- An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMDCompletedPhase 3Apellis Pharmaceuticals, Inc.NCT04770545Written as PEGCETACOPLAN (APL-2)
- Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft TransplantationWithdrawnPhase 3Apellis Pharmaceuticals, Inc.NCT07020832Written as Pegcetacoplan
- Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGNCompletedPhase 2Apellis Pharmaceuticals, Inc.NCT04572854Written as Pegcetacoplan
- An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative GlomerulonephritisActive, not recruitingPhase 3Apellis Pharmaceuticals, Inc.NCT05809531Written as Pegcetacoplan
- Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative GlomerulonephritisCompletedPhase 3Apellis Pharmaceuticals, Inc.NCT05067127Written as Pegcetacoplan
- Study to Evaluate a Pegcetacoplan (Syfovre®) Prefilled SyringeCompletedPhase 3Apellis Pharmaceuticals, Inc.NCT07214740Written as APL-2, Pegcetacoplan
- A Study of Pegcetacoplan for Patients With Transplant-associated Thrombotic Microangiopathy After Hematopoietic Stem Cell TransplantationCompletedPhase 2Swedish Orphan BiovitrumNCT05148299Written as Pegcetacoplan
- A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With Cold Agglutinin Disease (CAD)CompletedPhase 3Swedish Orphan BiovitrumNCT05096403Written as Pegcetacoplan
- MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS)TerminatedPhase 2Apellis Pharmaceuticals, Inc.NCT04579666Written as Pegcetacoplan (APL-2)
See all 33 studies that test pegcetacoplan →
As the comparator · 1 — what is tested is compared with pegcetacoplan
What changed recently
From the registry's own updates since Oct 18, 2026.
Started recruiting1
Results posted2
Newly registered1
Codes
What other systems call pegcetacoplan · ClinicalTrials.gg INT001596
- MeSH (NLM) C000716074pegcetacoplanConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) TO3JYR3BOUPEGCETACOPLANConfirmed FDA, NLM, Wikidata
- RxNorm 2557372One source FDA
- Wikidata Q106863504pegcetacoplanConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C121135PegcetacoplanOne source FDA
- DrugBank DB16694One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000716074 | pegcetacoplan | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | TO3JYR3BOU | PEGCETACOPLAN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2557372 | — | One source FDA |
| Wikidata | Q106863504 | pegcetacoplan | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C121135 | Pegcetacoplan | One source FDA |
| DrugBank | DB16694 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.